A Phase 1 interventional study of GZR18 injection、[14C]GZR18 injection in Overweight, Obese and Obesity, sponsored by Gan & Lee Pharmaceuticals.. Completed at 1 site in China. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Gan & Lee Pharmaceuticals. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing bofanglutide in Obesity — 3 open to participants now, 3 under way, 3 of them phase 3. bofanglutide · Obesity.
Among the 15 studies testing bofanglutide in Obesity, this one is the 15th largest by enrollment, is one of 6 that started in 2025, is one of 7 in phase 1, and was the 7th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →3 of the 15 studies testing bofanglutide in Obesity are open now, in 2 countries. Recruiting first, the newest first:
Gan & Lee Pharmaceuticals. · Sites in China
Ages 18+
Gan & Lee Pharmaceuticals. · Sites in China
Ages 18+
Carnot Laboratories · Sites in Mexico
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 55 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 5
First in 2021; this study’s year is marked. 6 started in 2025.
This study's enrollment of 6 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 140 across the 15 interventional studies. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 3 most frequent:
This study is registered under Gan & Lee Pharmaceuticals., one of the names counted as Gan & Lee Pharmaceuticals. Under that name alone:
Gan & Lee Pharmaceuticals. is the lead sponsor of 29 studies on the registry; 14 are open to participants now.
15 studies in Obesity by Gan & Lee Pharmaceuticals: 3 open now, 3 under way, 2 of them phase 3. Of 12 finished, 0 (0%) have results posted.
Among the 15 studies in Obesity by Gan & Lee Pharmaceuticals, this one is the 15th largest by enrollment, is one of 6 that started in 2025, is one of 8 in phase 1, and was the 7th registered.
Gan & Lee Pharmaceuticals’s Obesity studies by the year they started, since 2021.
2 of the studies testing bofanglutide in Obesity that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07150975Phase 3Gan & Lee Pharmaceuticals.Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects | 2027-06-30 |
| NCT07493057Phase 3Gan & Lee Pharmaceuticals.Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy | 2027-11-14 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies testing bofanglutide in Obesity, from their registry updates:
Among Gan & Lee Pharmaceuticals’s 15 in Obesity:
This tab as a report to print or save as PDF → With an account.
This trial is a Single-center, non-randomized, open-label, single-dose Mass Balance Study.
The study period of each subject consists of a screening period (D-21 to D-2), a baseline period (D-2 to D-1), a dosing and routine collection period (D1 to D36) and an intermittent collection and follow-up period (D36 to D78, during which subjects should visit the hospital once a week, 6 visits in total).
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 6 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Gan & Lee Pharmaceuticals. is the lead sponsor of 29 studies on the registry; 14 are open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: GZR18 injection、[14C]GZR18 injection
Participants will get a single dose of \[14C\]GZR18 injection
Primary Outcome Measure
The total radioactivity recovery at each interval and the cumulative total radioactivity recovery in excreta (urine and feces).
Time frame: Through study completion, an average of 1 year
Primary Outcome Measure
Percentage of parent drug and its metabolites (if applicable) in plasma in total radioactivity exposure in plasma; percentage of parent drug and its metabolites (if applicable) in urine and feces in administered dose; identification of major metabolites in plasma, urine, and feces.
Time frame: Through study completion, an average of 1 year
Primary Outcome Measure
Peak Plasma Concentration (Cmax)
Time frame: Through study completion, an average of 1 year
Primary Outcome Measure
Area under the plasma concentration versus time curve (AUC)
Time frame: Through study completion, an average of 1 year
Primary Outcome Measure
Ratio of total radioactivity concentration in whole blood to plasma
Time frame: Through study completion, an average of 1 year
Primary Outcome Measure
Time-To-Peak(Tmax)
Time frame: Through study completion, an average of 1 year
Primary Outcome Measure
Mean Residence Time
Time frame: Through study completion, an average of 1 year
Primary Outcome Measure
Half-Life Period(T1/2)
Time frame: Through study completion, an average of 1 year
PK parameters of GZR18 and its metabolites (if applicable) in plasma
Peak Plasma Concentration (Cmax)
Time frame: Through study completion, an average of 1 year
Safety Evaluation:Clinical safety evaluation during the study
weight and height will be combined to report BMI in kg/m\^2
Time frame: Average of 1 year
PK parameters of GZR18 and its metabolites (if applicable) in plasma
Area under the plasma concentration versus time curve (AUC)
Time frame: Through study completion, an average of 1 year
PK parameters of GZR18 and its metabolites (if applicable) in plasma
Time-To-Peak(Tmax)
Time frame: through study completion, an average of 1 year
PK parameters of GZR18 and its metabolites (if applicable) in plasma
Mean Residence Time
Time frame: through study completion, an average of 1 year
PK parameters of GZR18 and its metabolites (if applicable) in plasma
Half-Life Period(T1/2)
Time frame: through study completion, an average of 1 year
Safety Evaluation:Clinical safety evaluation during the study
laboratory tests (hematology, urinalysis, blood chemistry, coagulation function, stool analysis + occult blood and thyroid function)
Time frame: Average of 1 year
Ran from May 2025 to primary completion in Aug 2025, 3 months.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bofanglutide